FISH, N-MYC Amplification, Neuroblastoma
Use
Detection of MYCN (N‑MYC) gene amplification by fluorescence in situ hybridization (FISH) in neuroblastoma provides important prognostic information. MYCN amplification is found in a substantial proportion of neuroblastomas—approximately 20% overall and up to 40% in high‑stage tumors—and is associated with poorer outcomes such as lower overall survival and event‑free survival, especially in patients with low‑stage disease or metastatic disease in younger children; interpretation should be made in the context of clinical and pathological information.
Special Instructions
Provide clinical history and reason for referral at the time of test order. Insurance authorization is required prior to draw for outpatient collection but may not be necessary for inpatient collections.
Limitations
Specimen viability decreases during transit; do not freeze specimens. Formalin‑fixed, paraffin‑embedded tissue or bone marrow must be appropriately handled. Results interpretation should consider clinical presentation and staging; MYCN amplification lacks prognostic value in patients over 18 months with stage M disease.
Methodology
Chromosomal / Cytogenetics
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
1‑3 mm tumor biopsy
Minimum Volume
1 mm tumor biopsy
Container
Paraffin Embedded Tissue Block
Collection Instructions
Indicate source in comments, on specimen and on batch sheet.
Causes for Rejection
Received frozen